Scroll down to see more

Strategic Partners
Over the past five years, we have built a global network and value-creating strategic partnerships. We have established several global partnerships with leading pharmaceutical companies via in-licensing and clinical collaborations.
We will continue to expand our portfolio and explore partnership through strategic collaborations to maximize the value of our pipeline.
Business Development
We will keep seeking strategic collaborations worldwide that maximize the value of our pipeline. We believe such efforts will facilitate the development of a robust, well-diversified and globally competitive pipeline.

We have obtained exclusive global rights to develop, manufacture and commercialize LAE001, LAE002, LAE003 and LAE005 under our license agreement with Novartis and we are committed to seek additional partnerships to further optimize our product pipeline.

Combination Therapy Strategy

These opportunities include co-developments of novel treatment modalities for our existing clinical stage pipeline to treat drug resistant tumor types by delivering alternative solutions for patients.

Combination Therapy Strategy

As part of our core strategy to develop first-in-class or best-in-class drugs to market, we continue to seek novel research partnerships, in the pursuit to bring in house cutting-edge science and technologies in the field of drug development for cancer and liver diseases.

Holistic Approach
To support our long-term business strategy and to maximize the potential of our company’s assets, our corporate and business development group advances a holistic approach to continuously assess partnering opportunities with various global and regional stakeholders in the biopharmaceutical and biotech industry.
Guy Rosenthal, Ph.D. MBA
Vice President,Head of Corporate and Business Development

Dr. Guy Rosenthal joined Laekna Therapeutics in 2021 as Vice President, Head of Corporate and Business Development. As part of leading the corporate and business development group, his responsibilities span from searching for and evaluating potential assets, licensing, and alliance management to forming strategic partnerships and defining the company’s commercial strategy. Dr. Rosenthal is based in Los Angeles, California, USA.


Prior to joining Laekna, Dr. Rosenthal served as Business Development Officer at The University of California Los Angeles Technology Development Group (TDG). In his role, he led corporate development and investment efforts, amongst others, to commercialize biopharmaceutical assets, predominantly in the fields of Immuno-Oncology, Immunology, and Computational Biology.  


Dr. Rosenthal has also worked with Global R&D of Teva Pharmaceutical Industries (NASDAQ: TEVA) where he led global early-stage partnerships and has led innovative medical research in the Oncology and Neuro-Oncology fields when developing novel drug delivery platforms at VBL Therapeutics (NASDAQ: VBLT). Guy has completed numerous transactions including in/out-licensing of assets and creation of venture startups.


Dr. Rosenthal is also the Founder and Managing Director of The French Horn Fund, a nonprofit impact fund that invests in social enterprises and special-needs populations.   


Dr. Rosenthal holds an MBA from UCLA Anderson School of Management, B.Sc in Biotechnology and a Ph.D in both Biochemistry and Molecular Biology, Faculty of Life Sciences at Bar Ilan University, Israel.


Please contact our BD team:

Please contact our BD team:

RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation



Follow us on Linkedin